Skip to main content

Advertisement

SpringerLink
Log in

The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

The objective of this article was to assess the cost-effectiveness of screening strategies for cardiovascular diseases (CVD). A decision analytic model was constructed to estimate the costs and benefits of one-off screening strategies differentiated by screening age, sex and the threshold for initiating statin therapy (“uniform” or “age-adjusted”) from the Spanish NHS perspective. The age-adjusted thresholds were configured so that the same number of people at high risk would be treated as under the uniform threshold. Health benefit was measured in quality-adjusted life years (QALY). Transition rates were estimated from the European Prospective Investigation into Cancer and Nutrition (EPIC-CVD), a large multicentre nested case-cohort study with 12 years of follow-up. Unit costs of primary care, hospitalizations and CVD care were taken from the Spanish health system. Univariate and probabilistic sensitivity analyses were employed. The comparator was no systematic screening program. The base case model showed that the most efficient one-off strategy is to screen both men and women at 40 years old using a uniform risk threshold for initiating statin treatment (Incremental Cost-Effectiveness Ratio of €3,274/QALY and €6,085/QALY for men and women, respectively). Re-allocating statin treatment towards younger individuals at high risk for their age and sex would not offset the benefit obtained using those same resources to treat older individuals. Results are sensitive to assumptions about CVD incidence rates. To conclude, one-off screening for CVD using a uniform risk threshold appears cost-effective compared with no systematic screening. These results should be evaluated in clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Source of data: EPIC-CVD case-cohort study

Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sanderson, J.E., Mayosi, B., Yusuf, S., Reddy, S., Hu, S., Chen, Z., et al.: Global burden of cardiovascular disease. Heart (2007). https://doi.org/10.1136/hrt.2007.131060

    Article  PubMed  PubMed Central  Google Scholar 

  2. Visseren, F.L.J., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., Bäck, M., et al.: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. (2021). https://doi.org/10.1093/eurheartj/ehab484

    Article  PubMed  Google Scholar 

  3. Department of Health. Putting Prevention First. Vascular Checks: Risk Assessment and Management. http://data.parliament.uk/DepositedPapers/Files/DEP2008-0910/DEP2008-0910.pdf (2008). Accessed 2 Jul 2021

  4. Yebyo, H.G., Aschmann, H.E., Puhan, M.A.: Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: a modeling study. Ann. Intern. Med. (2019). https://doi.org/10.7326/M18-1279

    Article  PubMed  Google Scholar 

  5. Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž, Verschuren, W.M.M., et al.: European guidelines on cardiovascular disease prevention in clinical practice (Version 2012). Int. J. Behav. Med. (2012). https://doi.org/10.1007/s12529-012-9242-5

    Article  PubMed  Google Scholar 

  6. Moons, K.G.M., Kengne, A.P., Woodward, M., Royston, P., Vergouwe, Y., Altman, D.G., et al.: Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart (2012). https://doi.org/10.1136/heartjn1-2011-301246

    Article  PubMed  Google Scholar 

  7. Dyakova, M., Shantikumar, S., Colquitt, J.L., Drew, C.M., Sime, M., Maclver, J., et al.: Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease (Review). Cochrane Database Syst. Rev. (2016). https://doi.org/10.1002/14651858.CD010411.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  8. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. https://www.nice.org.uk/guidance/cg181/chapter/implementation-getting-started (2016). Accessed 6 Nov 2020.

  9. Epstein, D., García-Mochón, L., Kaptoge, S., Thompson, S.G.: Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. Eur. J. Heal. Econ. (2016). https://doi.org/10.1007/s10198-015-0753-2

    Article  Google Scholar 

  10. Lagerweij, G.R., de Wit, G.A., Moons, K.G.M., van der Schouw, Y.T., Veschuren, W.M.M., Dorresteijn, J.A.N., et al.: A new selection method to increase the health benefits of CVD prevention strategies. Eur. J. Prev. Cardiol. (2018). https://doi.org/10.1177/2047487317752948

    Article  PubMed  PubMed Central  Google Scholar 

  11. D’Agostino, R.B., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., et al.: General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation (2008). https://doi.org/10.1161/CIRCULATIONAHA.107.699579

    Article  PubMed  PubMed Central  Google Scholar 

  12. JBS2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005). https://doi.org/10.1136/hrt.2005.079988

  13. Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.I., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes, 4th edn. Oxford University Press, Oxford (2015)

    Google Scholar 

  14. Pennells, L., Kaptoge, S., Wood, A., Sweeting, M., Zhao, X., White, I., et al.: Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. Eur. Heart J (2019). https://doi.org/10.1093/eurheartj/ehy653

    Article  PubMed  Google Scholar 

  15. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998). https://doi.org/10.1056/nejm199811053391902

    Article  Google Scholar 

  16. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994). https://doi.org/10.1016/S0140-6736(94)90566-5

    Article  Google Scholar 

  17. Wang, H., Sun, W., Ji, Y., Shi, J., Xuan, Q., Wang, X., et al.: Trends in age-specific cerebrovascular disease in the european union. Int. J. Clin. Exp. Med. 7(11), 4165–4173 (2014)

    PubMed  PubMed Central  Google Scholar 

  18. Bhatnagar, P., Wickramasinghe, K., Wilkins, E., Townsend, N.: Trends in the epidemiology of cardiovascular disease in the UK. Heart (2016). https://doi.org/10.1136/bmj.k934

    Article  PubMed  Google Scholar 

  19. Riboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., et al.: European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. (2002). https://doi.org/10.1079/PHN2002394

    Article  PubMed  Google Scholar 

  20. Ricci, C., Wood, A., Muller, D., Gunter, M.J., Agudo, A., Boeing, H., et al.: Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. BMJ (2018). https://doi.org/10.1136/bmj.k934

    Article  PubMed  PubMed Central  Google Scholar 

  21. Royston, P., Lambert, P.C.: Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. Stata Press, College Station (2011)

    Google Scholar 

  22. Jones, E., Epstein, D., García-Mochón, L.: A procedure for deriving formulas to convert transition rates to probabilities for multistate markov models. Med. Decis. Mak (2017). https://doi.org/10.1177/027298X17696997

    Article  Google Scholar 

  23. Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H.M., Burke, M., Smith, G.D., et al.: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2013). https://doi.org/10.1002/14651858.CD004816.pub5

    Article  PubMed  PubMed Central  Google Scholar 

  24. Smith, D.W., Davies, E.W., Wissinger, E., Huelin, R., Matza, L.S., Chung, K.: A systematic literature review of cardiovascular event utilities. Expert Rev. Pharmacoeconomics Outcomes Res. (2013). https://doi.org/10.1586/14737167.2013.841545

    Article  Google Scholar 

  25. Dyer, M.T.D., Goldsmith, K.A., Sharples, L.S., Buxton, M.J.: A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual. Life Outcomes (2010). https://doi.org/10.1186/1477-7525-8-13

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brugts, J.J., Yetgin, T., Hoeks, S.E., Gotto, A.M., Shepherd, J., Westendorp, R.G.J., et al.: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ (2009). https://doi.org/10.1136/bmj.b2376

    Article  PubMed  PubMed Central  Google Scholar 

  27. Boletín Oficial de la Junta de Andalucía n°210. Orden de 14 de octubre de 2005, por la que se fijan los precios públicos de los servicios sanitarios prestados por Centros dependientes del Sistema Sanitario Público de Andalucía. Portal de la Junta de Andalucía. https://juntadeandalucia.es/boja/2005/210/boletin.210.pdf. (2005). Accessed 23 Jul 2020

  28. Petek, D., Petek-Ster, M., Tusek-Bunc, K.: Health behavior and health-related quality of life in patients with a high risk of cardiovascular disease. Zdr. Varst. (2018). https://doi.org/10.2478/sjph-2018-0006

    Article  PubMed  PubMed Central  Google Scholar 

  29. Navarro Moya, F., Carnero Pardo, C., Daponte Codina, A., del Río Urenda, S., Díez de los Ríos Carrasco, A., Domínguez Marmolejo, A., et al.: Proceso Asistencial Integrado. Riesgo vascular. Sevilla: Junta de Andalucía. Consejería de Salud (2010)

  30. Alva, M.L., Gray, A., Mihaylova, B., Leal, J., Holman, R.R.: The impact of diabetes-related complications on healthcare costs: New results from the UKPDS (UKPDS 84). Diabet. Med. (2015). https://doi.org/10.1111/dme.12647

    Article  PubMed  Google Scholar 

  31. Instituto Nacional de Estadística. Cálculo de variaciones del Indice de Precios de Consumo. http://www.ine.es/varipc/. Accessed 10 Aug 2016.

  32. BotPlus. https://botplusweb.portalfarma.com/botplus.aspx. Accessed 23 Jul 2021.

  33. Martín Ruiz, E., Olry de Labry, A., Epstein, D.: Prevención primaria de enfermedades cardiovasculares: una revisión de revisiones de intervenciones no farmacológicas. An. Sist. Sanit. Navar. 41(3), 355–369 (2018)

    PubMed  Google Scholar 

  34. Lemstra, M., Blackburn, D., Crawley, A., Fung, R.: Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can. J. Cardiol (2012). https://doi.org/10.1016/j.cjca.2012.05.007

    Article  PubMed  Google Scholar 

  35. Martin-Ruiz, E., Olry-de-Labry-Lima, A., Ocaña-Riola, R., Epstein, D.: Systematic review of the effect of adherence to statin treatment on critical cardiovascular events and mortality in primary prevention. J. Cardiovasc. Pharmacol. Ther. (2018). https://doi.org/10.1177/1074248417745357

    Article  PubMed  Google Scholar 

  36. Ministro de Sanidad. Resultados según la versión 32 de los APR-GRD. Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal de Años Anteriores. https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbdAnteriores.htm (2017). Accessed 20 Dec 2020.

  37. Ara, R., Brazier, J.E.: Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Heal. (2011). https://doi.org/10.1016/j.jval.2010.10.029

    Article  Google Scholar 

  38. Epstein, D.: Beyond the cost-effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal. Health Econ. (2019). https://doi.org/10.1002/hec.3884

    Article  PubMed  PubMed Central  Google Scholar 

  39. Vallejo-Torres, L., García-Lorenzo, B., Serrano-Aguilar, P.: Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. (2018). https://doi.org/10.1002/hec.3633

    Article  PubMed  Google Scholar 

  40. Eriksen, C., Rotar, O., Toft, U., Jørgensen, T.: What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? Copenhagen: WHO Regional Office for Europe, 2021 (WHO Health Evidence Nerwork (HEN) Evidence Synthesis Report 71). https://apps.who.int/iris/bitstream/handle/10665/338530/9789289055376-eng.pdf. Accessed 2 Jan 2021.

  41. Johannesson, M.: At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur. Heart J. (2001). https://doi.org/10.1053/euhj.2000.2484

    Article  PubMed  Google Scholar 

  42. Damen, J.A., Tajouheshnia, R., Heus, P., Moons, K.G.M., Reitsma, J.B., Scholten, R.J.P.M., et al.: Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: A systematic review and meta-analysis. BMC Med. (2019). https://doi.org/10.1186/s12916-019-1340-7

    Article  PubMed  PubMed Central  Google Scholar 

  43. Joy, T.R., Hegele, R.A.: Narrative review: statin-related myopathy. Ann. Intern. Med. (2009). https://doi.org/10.7326/0003-4819-150-12-200906160-00009

    Article  PubMed  Google Scholar 

  44. Ahmad, Z.: Statin intolerance. Am. J. Cardiol. (2014). https://doi.org/10.1016/j.amjcard.2014.02.033

    Article  PubMed  Google Scholar 

  45. Wood, F.A., Howard, J.P., Finegold, J.A., Nowbar, A.N., Thompson, D.M., Arnold, A.D., et al.: N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N. Engl. J. Med. (2020). https://doi.org/10.1056/nejmc2031173

    Article  PubMed  PubMed Central  Google Scholar 

  46. Martín Ruiz, E., Olry-de-Labry-Lima, A., Epstein, D.: The benefits and risks of statins for primary prevention of mortality and cardiovascular events: umbrella review. Eur J Clin Pharm. 18(5), 335–340 (2016)

    Google Scholar 

  47. Goff, D.C., Lloyd-Jones, D.M., Bennett, G., Coady, S., D’Agostino, R.B., Gibbons, R., et al.: 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. (2014). https://doi.org/10.1016/j.jacc.2013.11.005

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kypridemos, C., Allen, K., Hickey, G.L., Guzman-Castillo, M., Bandosz, P., Buchan, I., et al.: Cardiovascular screening to reduce the burden from cardiovascular disease: Microsimulation study to quantify policy options. BMJ (2016). https://doi.org/10.1136/bmj.i2793

    Article  PubMed  PubMed Central  Google Scholar 

  49. Patel, R., Barnard, S., Thompson, K., Lagord, C., Clegg, E., Worrall, R., et al.: Evaluation of the uptake and delivery of the NHS Health Check programme in England, using primary care data from 9.5 million people: A cross-sectional study. BMJ Open (2020). https://doi.org/10.1136/bmjopen-2020-042963

    Article  PubMed  PubMed Central  Google Scholar 

  50. Heller, D.J., Coxson, P.G., Penko, J., Pletcher, M.J., Goldman, L., Odden, M.C., et al.: Evaluating the impact and cost- effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. Circulation (2017). https://doi.org/10.1161/CIRCULATIONAHA.117.027067

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom), Hyblean Association for Epidemiological Research, AIRE ONLUS, EPIC-Ragusa (Italy).

Funding

The EPIC-CVD coordinating centre was supported by core funding from the European Commission Framework Programme 7 (HEALTH-F2-2012-279233), European Research Council (268834), Novartis, UK Medical Research Council (G0800270; MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The study was also supported by International Agency for Research on Cancer (IARC), the Department of Epidemiology and Biostatistics (School of Public Health, Imperial College London) and the Spanish Association of Health Economics (Research Fellowship on Health Economics and Health Services, 12,000€).

Author information

Authors and Affiliations

  1. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Avda Monforte de Lemos 3-5, 28029, Madrid, Spain

    Zuzana Špacírová, Leticia García-Mochón, Miguel Rodríguez Barranco, María José Sánchez Pérez, Jaime Espín & Sandra M. Colorado-Yohar

  2. Escuela Andaluza de Salud Pública (EASP), Cuesta del Observatorio 4. Campus Universitario de Cartuja, 18011, Granada, Spain

    Zuzana Špacírová, Leticia García-Mochón, Miguel Rodríguez Barranco, María José Sánchez Pérez & Jaime Espín

  3. Instituto de Investigación Biosanitaria Ibs.Granada, 18012, Granada, Spain

    Zuzana Špacírová, Leticia García-Mochón, Miguel Rodríguez Barranco, María José Sánchez Pérez & Jaime Espín

  4. Cardiovascular Epidemiology Unit, Strangeways Research Laboratory, Department of Public Health and Primary Care, University of Cambridge, 2 Worts’ Causeway, Cambridge, CB1 8RN, UK

    Stephen Kaptoge & Lois Kim

  5. Department of Preventive Medicine and Public Health, University of Granada, 18071, Granada, Spain

    María José Sánchez Pérez

  6. The Danish Cancer Society Research Centre, Strandboulevarden 49, 2100, Copenhagen, Denmark

    Nicola P. Bondonno & Anne Tjønneland

  7. Institute for Nutrition Research, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Dr, Perth, 6027, Australia

    Nicola P. Bondonno

  8. Department of Public Health, University of Copenhagen, Copenhagen, Denmark

    Anne Tjønneland

  9. International Agency for Research on Cancer, World Health Organization, Lyon, France

    Elisabete Weiderpass

  10. Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133, Milan, Italy

    Sara Grioni

  11. Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Via Santena 7, 10126, Turin, Italy

    Carlotta Sacerdote

  12. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany

    Catarina Schiborn & Matthias B. Schulze

  13. German Center for Diabetes Research (DZD), Munich, Germany

    Catarina Schiborn & Matthias B. Schulze

  14. Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network – ISPRO, Florence, Italy

    Giovanna Masala

  15. Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain

    Sandra M. Colorado-Yohar

  16. Research Group on Demography and Health, National Faculty of Public Health, Univesity of Antioquia, Medellín, Colombia

    Sandra M. Colorado-Yohar

  17. Julius Center for Health Sciences and Primary Care, UMC Utrecht, Trecht University, Utrecht, The Netherlands

    Karel G. M. Moons

  18. Department of Clinical Sciences, Lund University, Malmö, Sweden

    Gunnar Engström

  19. Institute of Nutritional Science, University of Potsdam, Potsdam, Germany

    Matthias B. Schulze

  20. Ubisoft France, Floresco, 2 Avenue Pasteur, 94160, Saint-Mandé, France

    Léa Bresson

  21. Navarra Public Health Institute, Pamplona, Spain

    Concepción Moreno-Iribas

  22. IdiSNA, Navarra Institute for Health Research, Pamplona, Spain

    David Epstein

  23. University of Granada, Granada, Spain

    David Epstein

Authors
  1. Zuzana Špacírová
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Kaptoge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leticia García-Mochón
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miguel Rodríguez Barranco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María José Sánchez Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicola P. Bondonno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anne Tjønneland
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elisabete Weiderpass
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sara Grioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jaime Espín
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Carlotta Sacerdote
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Catarina Schiborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Giovanna Masala
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sandra M. Colorado-Yohar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lois Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Karel G. M. Moons
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Gunnar Engström
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Matthias B. Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Léa Bresson
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Concepción Moreno-Iribas
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. David Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Design of the study: LGM, JE, DE. Data collection: MRB, MJSP, AT, SG, CS, GM, GE, MBS. Estimation of the age-adjusted risk thresholds: SK, LB. Analysis and interpretation of data: ZS, DE, LB, LGM. Drafting the article: ZS, DE. Critical revision of the article: NPB, AT, EW, CS, CSch, SMCY, LK, KGMM, GE, MBS, CMI. All authors approved the final version of the article.

Corresponding author

Correspondence to Zuzana Špacírová.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material. The spreadsheets related to this article is available under doi: 10.17632/ysm4yj24xh.1.

Supplementary file1 (DOCX 39 KB)

Supplementary file2 (DOCX 293 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Špacírová, Z., Kaptoge, S., García-Mochón, L. et al. The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease. Eur J Health Econ 24, 1033–1045 (2023). https://doi.org/10.1007/s10198-022-01533-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-022-01533-y

Keywords

Search

Navigation